We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
- Authors
Pitt, Bertram; Agarwal, Rajiv; Anker, Stefan D.; Ruilope, Luis M.; Rossing, Peter; Ahlers, Christiane; Brinker, Meike; Joseph, Amer; Lambelet, Marc; Lawatscheck, Robert; Filippatos, Gerasimos S.
- Abstract
Key Points: Question: Does mineralocorticoid receptor blockade with finerenone protect against pneumonia and COVID-19 adverse events (AEs) in patients with type 2 diabetes and chronic kidney disease? Findings: In this secondary analysis of 2 randomized clinical trials including 12 999 patients from 2 randomized clinical trials, the incidence of treatment-emergent pneumonia AEs and serious AEs was significantly lower with finerenone vs placebo. The rate of COVID-19 AEs was also significantly reduced with finerenone. Meaning: These findings suggest that finerenone treatment may be associated with protection from pneumonia and COVID-19 in patients with chronic kidney disease and type 2 diabetes; however, further clinical studies may be warranted. This secondary analysis assesses the association of finerenone with pneumonia and COVID-19 adverse events in patients from 2 randomized clinical trials with type 2 diabetes and chronic kidney disease. Importance: Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19–associated adverse events and mortality. Therefore, the anti-inflammatory effects of mineralocorticoid receptor antagonists via blockade of the mineralocorticoid receptor may alter the risk of pneumonia and COVID-19–associated adverse events in patients with chronic kidney disease and type 2 diabetes. Objective: To evaluate whether the selective, nonsteroidal mineralocorticoid receptor antagonist finerenone is associated with protection against pneumonia and COVID-19 adverse events in patients with type 2 diabetes and chronic kidney disease. Design, Setting, and Participants: This secondary analysis used patient-level data from FIDELITY, a prespecified pooled analysis of 2 multicenter, double-blind, placebo-controlled, event-driven, phase 3 randomized clinical trials: FIDELIO-DKD and FIGARO-DKD, conducted between September 2015 and February 2021. Patients in FIDELIO-DKD or FIGARO-DKD with type 2 diabetes and chronic kidney disease (urine albumin to creatine ratio, 30-5000 mg/g, estimated glomerular filtration rate ≥25 mL/min/1.73 m2) were assessed. Data were analyzed from May 15, 2021, to July 28, 2022. Exposure: Patients were randomized to finerenone (10 or 20 mg once daily) or matching placebo. Main Outcomes and Measures: The main outcomes were investigator-reported incidences of treatment-emergent infective pneumonia adverse events and serious adverse events (during and up to 3 days after treatment) and any COVID-19 adverse events. Results: Of 13 026 randomized patients (mean [SD] age, 64.8 [9.5] years; 9088 [69.8%] men), 12 999 were included in the FIDELITY safety population (6510 patients receiving finerenone; 6489 patients receiving placebo). Over a median (range) treatment duration of 2.6 (0-5.1) years, finerenone was consistently associated with reduced risk of pneumonia and serious pneumonia vs placebo. Overall, 307 patients (4.7%) treated with finerenone and 434 patients (6.7%) treated with placebo experienced pneumonia (hazard ratio [HR], 0.71; 95% CI, 0.64-0.79; P <.001). Serious pneumonia occurred in 171 patients (2.6%) treated with finerenone and 250 patients (3.9%) treated with placebo (HR, 0.69; 95% CI, 0.60-0.79; P <.001). Incidence proportions of COVID-19 adverse events were 86 patients (1.3%) in the finerenone group and 118 patients (1.8%) in the placebo group (HR, 0.73; 95% CI, 0.60-0.89; P =.002). Conclusions and Relevance: These findings suggest that mineralocorticoid receptor blockade with finerenone was associated with protection against pneumonia and COVID-19 adverse events in patients with type 2 diabetes and chronic kidney disease. Further clinical studies may be warranted. Trial Registration: ClinicalTrials.gov identifiers: FIDELIO-DKD: NCT02540993; FIGARO-DKD: NCT02545049
- Subjects
PNEUMONIA prevention; PNEUMONIA; CHRONIC kidney failure; ALBUMINS; HOSPITAL emergency services; COVID-19; CONFIDENCE intervals; TYPE 2 diabetes; MINERALOCORTICOIDS; TREATMENT effectiveness; COMPARATIVE studies; DESCRIPTIVE statistics; ADVERSE health care events; DATA analysis software; SECONDARY analysis; CREATININE; PROPORTIONAL hazards models; CHEMICAL inhibitors
- Publication
JAMA Network Open, 2022, Vol 5, Issue 10, pe2236123
- ISSN
2574-3805
- Publication type
Article
- DOI
10.1001/jamanetworkopen.2022.36123